AZ
US election: Republicans hold back Democrats, narrowing path to Senate control
The battle for power in the Senate tightened into Wednesday as Democrats picked up a seat in Colorado, but suffered a setback in Alabama, and Republicans held their own in high-profile races in South Carolina, Iowa, Texas and Kansas, dramatically narrowing the political map. Republicans fought to retain their Senate majority by turning back a surge of Democrats challenging allies of President Donald Trump, and the Democrats’ various paths to seizing control were growing more limited. With several contests still too early to call, and one Georgia race heading to a January runoff, the final verdict is expected to drag on. Democrats gained a seat when ex-Gov. John Hickenlooper ousted GOP Sen. Cory Gardner in Colorado, a must-win to flip the Senate, but couldn’t hold on in Alabama, where forme...
UEFA releases possible dates for Champions League games
UEFA’s plan to complete the Champions League and Europa League continues. The plan says that they will be played throughout the month of August once the leagues are done in July. UEFA have an idea which is to end the season by the end of August. Therefore, the domestic leagues need to be completed by the end of July. The proposal is for the remaining last 16 games to be played in the first week of the month. On 26th and 29th August, Gdansk and Istanbul will host the Europa League and Champions League finals respectively. ‘Marca’ says that they will try and stick to that instead of playing both the finals at the same venue. There are 17 Champions League and 27 Europa League matches left to play. Confirmation of the new calendar depends first on leagues getting back underway and then on the ...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
